Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486568 | 0.88 | MAPK1 (0.43) | ALDH1A1SMN1; SMN2TAS1R3TAS1R1MAPK1 | |
| SCHEMBL16554097 | 0.85 | ERN1 (0.38) | ALDH1A1TAS1R3TAS1R1GAAMAPK1 | |
| SCHEMBL5481803 | 0.85 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2TAS1R3TAS1R1GAA | |
| SCHEMBL6834732 | 0.83 | HTT (0.42) | ALDH1A1TAS1R3TAS1R1KDM4EMAPK1 | |
| SCHEMBL16554306 | 0.77 | ACACB (0.38) | ALDH1A1SMN1; SMN2TAS1R3TAS1R1GAA | |
| SCHEMBL1537457 | 0.75 | XDH (0.41) | ALDH1A1SMN1; SMN2TAS1R3TAS1R1KDM4E | |
| SCHEMBL8794058 | 0.74 | TAS1R3 (0.39) | ALDH1A1SMN1; SMN2TAS1R3TAS1R1LMNA | |
| SCHEMBL12269966 | 0.74 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TAS1R3TAS1R1GAA | |
| SCHEMBL1152535 | 0.73 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TAS1R3TAS1R1GAA | |
| SCHEMBL16554601 | 0.71 | ERN1 (0.37) | ALDH1A1GAAMAPK1CNR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213160-A1 | 2,4,6-Phenyl-Substituted Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110213160-A1 | 2,4,6-Phenyl-Substituted Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110213160-A1 | 2,4,6-Phenyl-Substituted Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110195842-A1 | 2,4,6-Phenyl-Substituted Cyclic Ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110195842-A1 | 2,4,6-Phenyl-Substituted Cyclic Ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110195842-A1 | 2,4,6-Phenyl-Substituted Cyclic Ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-08-11 | — | — | US | disclosed |
| US-7947704-B2 | 2,4,6-phenyl-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-05-24 | — | — | US | disclosed |
| US-7947704-B2 | 2,4,6-phenyl-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-05-24 | — | — | US | disclosed |
| US-7947704-B2 | 2,4,6-phenyl-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-05-24 | — | — | US | disclosed |
| US-20070298968-A1 | 2,4,6-Phenyl-Substituted Cyclic Ketoenols | BAYER CROPSCIENCE AG (DE) | 2007-12-27 | — | — | US | disclosed |
| US-20070298968-A1 | 2,4,6-Phenyl-Substituted Cyclic Ketoenols | BAYER CROPSCIENCE AG (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1732930-A2 | 2,4,6-PHENYLSUBSTITUTED CYCLIC KETOENOLES | Bayer CropScience Aktiengesellschaft (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092897-A2 | 2,4,6-PHENYLSUBSTITUTED CYCLIC KETOENOLES | BAYER CROPSCIENCE AG (DE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298968-A1 | 2,4,6-Phenyl-Substituted Cyclic Ketoenols | CYP4X1, KCNE1, KDM4E | ALDH1A1 2441/4885SMN1; SMN2 4169/4885TAS1R3 4459/4885 |
| US-20110195842-A1 | 2,4,6-Phenyl-Substituted Cyclic Ketoenols | CYP4X1, KCNE1, KDM4E | ALDH1A1 2441/4885SMN1; SMN2 4169/4885TAS1R3 4459/4885 |
| US-20110213160-A1 | 2,4,6-Phenyl-Substituted Derivatives | CYP4X1, KDM4E, KCNE1 | ALDH1A1 2129/4885SMN1; SMN2 4082/4885TAS1R3 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.